Clinical DataThe updated results are trending positively, with the new sub-analysis supporting dose responsive efficacy for briquilimab, and safety continuing to look promising.
Market OpportunityBEACON now includes omalizumab-naive patients, which could grow the addressable population for JSPR.
Safety ProfileThe briquilimab study continues to demonstrate a best-in-class tolerability profile, giving JSPR the potential to differentiate.